Simple Summary Multiple myeloma is a haematological malignancy due to a proliferation of
clonal plasma cells. The medullary milieu consists of a bone marrow microenvironment …

Использование новых подходов в лечении рецидивов и рефрактерных форм
множественной миеломы (ММ) привело к существенному улучшению общей …

Background Because patients with newly diagnosed multiple myeloma (NDMM) do not
always receive any treatment beyond first-line (1L) therapy, it is imperative that patients …

Assessment of minimal residual disease (MRD) is becoming a standard diagnostic tool for
curable hematological malignancies such as chronic and acute myeloid leukemia. Multiple …

Introduction The prevalence of multiple myeloma (MM) has gradually increased over the last
few decades in India due to growing population, better disease awareness, and improved …

Background Since no randomized controlled trials have directly compared the efficacy and
safety of immunotherapy with daratumumab versus lenalidomide/bortezomib …

Introduction Daratumumab plus lenalidomide and dexamethasone (D-Rd) and bortezomib
plus lenalidomide and dexamethasone (VRd) are commonly used treatment combinations …

Background Bortezomib-melphalan-prednisone (VMP) and lenalidomide-dexamethasone
(Rd) remain the standard treatments for transplant-ineligible patients with newly diagnosed …

Aim: Obtain clinical consensus on factors impacting first-line prescribing for transplant-
ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). Materials & …

Multiple myeloma (MM) is the second most common hematologic cancer, with an estimated
35,730 new cases and 12,590 deaths annually in the United States (Siegel et al., 2023) …